Colrain Capital’s Sanofi SNY Stock Holding History

Colrain Capital’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-11,500	Closed	-$546K	–	85
2015 Q3	$546K	Sell	11,500 -22,500	-66%	-$1.15M	0.06%	71
2015 Q2	$1.68M	Sell	34,000 -27,720	-45%	-$1.4M	0.15%	60
2015 Q1	$3.05M	Sell	61,720 -2,000	-3%	-$95.6K	0.25%	54
2014 Q4	$2.91M	Buy	+63,720	New	+$3.09M	0.22%	60

Other funds holding SNY

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Colrain Capital's SNY Position: Q4 2015 in Review

Colrain Capital sold out of Sanofi (SNY) in Q4 2015, closing a stake of 11,500 shares — an estimated $546K sold.

Colrain Capital first reported a position in SNY in Q4 2014 and held it in 4 quarters. The position peaked at $3.05M in Q1 2015. 477 funds tracked by Wall St. Rank hold SNY as of Q4 2015.

Colrain Capital reported no remaining Sanofi position as of Q4 2015 after selling out during the quarter.
Colrain Capital sold 11,500 Sanofi shares in Q4 2015, an estimated $546K.
Colrain Capital first reported a position in Sanofi in Q4 2014 and held it in 4 quarters.
Colrain Capital's Sanofi position peaked at $3.05M in Q1 2015.
477 funds tracked by Wall St. Rank held Sanofi as of Q4 2015.

Based on Colrain Capital's 13F filing for Q4 2015, filed 5 Feb 2016.